CD33 and acute myeloid leukemia: Additional killing assays using anti-CD33 and anti-CD123-targeting CAR T-cells together with isogenic MOLM13-TP53 and MV4-11-TP53 AML cells confirmed the complete reversal of the resistance of TP53-mutant AML cells against CAR T-cell killing (Fig. EV4E).